Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis

Overview

Journal J Oncol

Specialty Oncology

Date 2020 Apr 8

PMID 32256584

Citations 6

Authors

Qing Ma

Jing Wang

Yaoyao Ren

Fanlu Meng

Lili Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Osimertinib is the first-line therapeutic option for the T790M-mutant non-small-cell lung cancer and the acquired resistance obstructs its application. It is an urgent challenge to identify the potential mechanisms of osimertinib resistance for uncovering some novel therapeutic approaches.

Methods: In the current study, the cell metabolomics based on ultra-high-performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometry and the qualitative and tandem mass tags quantitative proteomics were performed.

Results: 54 differential metabolites and 195 differentially expressed proteins were, respectively, identified. The amino acids metabolisms were significantly altered. HIF-1 signaling pathway modulating P-glycoproteins expression, PI3K-Akt pathway regulating survivin expression, and oxidative phosphorylation were upregulated, while arginine and proline metabolism regulating NO production and glycolysis/gluconeogenesis were downregulated during osimertinib resistance.

Conclusion: The regulation of HIF-1 and PI3K-Akt signaling pathway, energy supply process, and amino acids metabolism are the promising therapeutic tactics for osimertinib resistance.

Citing Articles

NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway.

Wang Y, Wang B, Zhou L, Wan Y, Zheng Y, Zhou L Am J Cancer Res. 2025; 14(12):5680-5696.

PMID: 39803652 PMC: 11711526. DOI: 10.62347/RLVZ6860.

Cross-omics strategies and personalised options for lung cancer immunotherapy.

Yan Y, Shen S, Li J, Su L, Wang B, Zhang J Front Immunol. 2024; 15:1471409.

PMID: 39391313 PMC: 11465239. DOI: 10.3389/fimmu.2024.1471409.

A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer.

Kannampuzha S, Mukherjee A, Wanjari U, Gopalakrishnan A, Murali R, Namachivayam A Vaccines (Basel). 2023; 11(2).

PMID: 36851259 PMC: 9960365. DOI: 10.3390/vaccines11020381.

Dysregulated Metabolism in EGFR-TKI Drug Resistant Non-Small-Cell Lung Cancer: A Systematic Review.

Babuta J, Hall Z, Athersuch T Metabolites. 2022; 12(7).

PMID: 35888768 PMC: 9316206. DOI: 10.3390/metabo12070644.

Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.

Qian X, Zhang H, Li Q, Ma G, Chen Z, Ji X Clin Transl Med. 2022; 12(6):e947.

PMID: 35735103 PMC: 9218934. DOI: 10.1002/ctm2.947.

References

Giaccone G . Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005; 23(14):3235-42. DOI: 10.1200/JCO.2005.08.409. View

Sun H, Olson K, Gao C, Prosdocimo D, Zhou M, Wang Z . Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation. 2016; 133(21):2038-49. PMC: 4879058. DOI: 10.1161/CIRCULATIONAHA.115.020226. View

Mathupala S, Ko Y, Pedersen P . The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta. 2010; 1797(6-7):1225-30. PMC: 2890051. DOI: 10.1016/j.bbabio.2010.03.025. View

Offin M, Somwar R, Rekhtman N, Benayed R, Chang J, Plodkowski A . Acquired and Gene Fusions as Mechanisms of Resistance to Osimertinib in -Mutant Lung Cancers. JCO Precis Oncol. 2019; 2. PMC: 6447364. DOI: 10.1200/PO.18.00126. View

Villalobo A . Nitric oxide and cell proliferation. FEBS J. 2006; 273(11):2329-44. DOI: 10.1111/j.1742-4658.2006.05250.x. View

Adewumi Akanji M, Rotimi D, Adeyemi O . Hypoxia-Inducible Factors as an Alternative Source of Treatment Strategy for Cancer. Oxid Med Cell Longev. 2019; 2019:8547846. PMC: 6710762. DOI: 10.1155/2019/8547846. View

Bal-Price A, Gartlon J, Brown G . Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion. Nitric Oxide. 2005; 14(3):238-46. DOI: 10.1016/j.niox.2005.10.002. View

Wang Y, Minko T . A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug. Biochem Pharmacol. 2004; 68(10):2031-42. DOI: 10.1016/j.bcp.2004.07.017. View

Alvarez-Calderon F, Gregory M, Pham-Danis C, DeRyckere D, Stevens B, Zaberezhnyy V . Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2014; 21(6):1360-72. PMC: 4359967. DOI: 10.1158/1078-0432.CCR-14-2146. View

10.

Neill K, Saller J, Al Diffalha S, Centeno B, Malafa M, Coppola D . EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas. Cancer Genomics Proteomics. 2018; 15(3):201-205. PMC: 5971012. DOI: 10.21873/cgp.20078. View

11.

Heigener D, Reck M . Lung cancer in 2017: Giant steps and stumbling blocks. Nat Rev Clin Oncol. 2017; 15(2):71-72. DOI: 10.1038/nrclinonc.2017.178. View

12.

Cross D, Ashton S, Ghiorghiu S, Eberlein C, Nebhan C, Spitzler P . AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4(9):1046-61. PMC: 4315625. DOI: 10.1158/2159-8290.CD-14-0337. View

13.

Nicholson J, Connelly J, Lindon J, Holmes E . Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002; 1(2):153-61. DOI: 10.1038/nrd728. View

14.

Wang M, Lu K, Zhu S, Dia E, Vivanco I, Shackleford G . Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006; 66(16):7864-9. DOI: 10.1158/0008-5472.CAN-04-4392. View

15.

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

16.

Masters G, Johnson D, Temin S . Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Oncol Pract. 2018; 12(1):90-93. DOI: 10.1200/JOP.2015.008524. View

17.

Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1689-99. DOI: 10.1056/NEJMoa1411817. View

18.

Comerford K, Wallace T, Karhausen J, Louis N, Montalto M, Colgan S . Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002; 62(12):3387-94. View

19.

Xia S, Yu S, Yuan X, Xu S . [Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line]. Zhonghua Yi Xue Za Zhi. 2004; 84(8):663-6. View

20.

Lim S, Syn N, Cho B, Soo R . Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018; 65:1-10. DOI: 10.1016/j.ctrv.2018.02.006. View